StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug ...
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...
On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...
GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review a Biologics License Application, BLA, for Blenrep in combinations with bortezomib plus dexamethasone and ...
REGENECYTE™ is an allogeneic hematopoietic stem cell therapy derived from human umbilical cord blood. It is approved for unrelated donor hematopoietic progenitor cell transplantation procedures ...
1d
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.
Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback